Market revenue in 2023 | USD 66.2 million |
Market revenue in 2030 | USD 251.2 million |
Growth rate | 21% (CAGR from 2023 to 2030) |
Largest segment | Gmp grade |
Fastest growing segment | GMP Grade |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | R&D Grade, GMP Grade |
Key market players worldwide | Charles River Laboratories International Inc, Danaher Corp, Kaneka Corp, Eurofins Scientific SE, Lonza Group Ltd, Akron Biotechnology, Luminous BioSciences, Lonza Group Ltd ADR, Cell & Gene Therapy, Nature Technology, VGXI |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna manufacturing market will help companies and investors design strategic landscapes.
Gmp grade was the largest segment with a revenue share of 86.1% in 2023. Horizon Databook has segmented the Germany plasmid dna manufacturing market based on r&d grade, gmp grade covering the revenue growth of each sub-segment from 2018 to 2030.
Germany is second in terms of the number of gene therapy clinical trials in Europe. A substantial number of companies have their facilities set up here, which is anticipated to support the rapid commercialization of drugs.
Germany is the first country where the recently approved gene therapy treatment has been utilized. It is expected to witness significant growth in the number of trials and approval of drugs in the coming years, owing to an increase in the number of companies being set up and the support provided by governments in finding feasible treatment options for genetic disorders & various cancers.
For instance, in June 2021, the German Parliament approved legislation to accelerate patient access to cell & gene therapies. This new legislation addressed the bureaucratic barrier that hampers their availability in hospitals.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany plasmid dna manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Germany plasmid dna manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account